Acino Helps Acquisition By Private Collateral Firms Acino Group.

Genetic Engineering & Biotechnology News has retained its placement as the number one biotech publisher around the world since its launch in 1981. GEN publishes a print edition 21 times a calendar year and has additional exclusive editorial content online, like evaluation and news as well as blogs, podcasts, webinars, polls, videos, and program notes. GEN’s unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, in addition to diagnostics, to commercialization and bioprocessing. Alzheimer’s disease, the most common type of dementia , is the 6th leading reason behind death, and affects 1 in 8 people – – a lot more than breast tumor.6 million people with Alzheimer’s disease in the world, but this true number is expected to double every twenty years.Alliance to build up and commercialize fully-individual anti-anthrax antibody Medarex, Inc. And PharmAthene, Inc., a held biotechnology company focused on the development of biodefense products privately, announced today that the companies have entered right into a collaboration agreement under that your companies plan to develop and commercialize MDX-1303, a individual monoclonal antibody targeting the Bacillus anthracis protective antigen fully. MDX-1303 originated by Medarex using its UltiMAb Human Antibody Advancement System, and this antibody happens to be in preclinical development by Medarex for make use of against human anthrax infections. Under the terms of the contract, Medarex and PharmAthene have agreed to jointly continue to investigate the potential for MDX-1303 to be used as a therapeutic for individuals with active disease as well as for prophylactic treatment of individuals subjected to anthrax.